

Shionogi Announces Corporate Reorganization and Personnel Reassignment

OSAKA, Japan, November 25, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Shionogi will implement the following corporate reorganization and personnel reassignment as of January 1, 2023.

1. Corporate Reorganization (see attached organization chart)

New establishment of the Business Administration Office

Toward the realization of STS2030, in July 2022 we established supervisory organizations in charge of each major value chain in order to further clarify business execution responsibilities and strengthen cooperation between related departments. As the quality and speed of decision-making by each supervisory unit improves, it become increasingly important to collect and share financial and non-financial information in a timely manner, and to monitor and verify management conditions. The Business Administration Office will be newly established under the Finance & Accounting Department to combine, visualize, and analyze vast amounts of information on management resources, leading to business improvement.

| New (or continuing) Position | Name | Present Position | |
|--|------------------|---|--|
| R&D Supervisory Unit | | | |
| Vice President, Pharmacovigilance Department and President, Shionogi Pharmacovigilance Center Co., Ltd. | Masako Kaneto | Vice President, Pharmacovigilance Department | |
| Corporate Supervisory Unit | | | |
| Senior Executive Officer, Senior Vice President, Corporate Strategy Division | Ryuichi Kiyama | Senior Executive Officer, Senior Vice President, Corporate Strategy Division and Corporate Planning Department | |
| Vice President, Corporate Planning Department | Takashi Mizukawa | Shionogi Pharma Co., Ltd. | |
| Vice President, Sustainability Management Department | Yuka Niimi | President, Shionogi Pharmacovigilance Center Co., Ltd. | |
| Vice President, Finance & Accounting Department | Masako Kudou | Vice President, Sustainability Management Department | |
| Senior Director, Finance & Accounting Department, Business Administration Office | Takuji Fujiwara | Corporate Planning Department | |

2. Personnel Reassignments (Effective; January 1, 2023)

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html

SHIONOGI Divisions (January 1, 2023)

| | | Corporate Executive Meeting | |
|---|---|--|--|
| he Annual General Meeting of Shareholders | Board of Directors | | |
| | Chief Executive Officer and Representative Director | Compliance Committee | |
| Board | of Auditors | | |
| | | | |
| &D Supervisory Unit | Research Division | Laboratory for Drug Discovery and Disease Research | |
| | | Laboratory for Medicinal Chemistry Research | |
| | | Laboratory for Drug Discovery and Development | |
| | | API R&D Laboratory | |
| | | Formulation R&D Laboratory | |
| | | Intellectual Property Department | |
| | Drug Development and Regulatory Science Division | Project Management Department | |
| | Drug Development and Regulatory Science Division | Clinical Research Department | |
| | | Medical Science Department | |
| | | Regulatory Affairs Department | |
| | | Pharmacovigilance Department | |
| | | | Biostatistics Center |
| | | | |
| | Biopharmaceutical Research Division | Laboratory for Bio-Drug Discovery | |
| | | Laboratory for Bio-Modality Research | |
| | | Analysis and Evaluation Laboratory | |
| | | | |
| | | Business Development Department | |
| | | Investment Strategy Department | |
| ealthcare Business Supervisory Unit | Pharmaceutical Commercial Division | Promotion Department - Region 1 | |
| ealthcare business supervisory offic | rhamaceutical Commercial Division | Promotion Department - Region 2 | |
| | | Promotion Department - Region 3 | |
| | | Promotion Department - Region 4 | |
| | | Promotion Department - Region 5 | |
| | | Distribution Management Department | |
| | | | Sales Promotion Office |
| | | | Specialty Product Office |
| | | | |
| | Integrated Disease Care Division | New Product Planning Department | |
| | | Medical Affairs Department | Drug Information Center |
| | | Corporate Social Responsibility Department | Office for Children's Bright Future |
| | | | Office for Stewardship to Proper Use of Medic |
| | | New Business Promotion Department | |
| | | | Academia Collaboration Office |
| | | Government Affairs Department | |
| | | Vaccine and Diagnostic Drug Department | Diagnostic Drug Office |
| | | | Partnership Promotion Office |
| | | Tokyo Branch Office | |
| Supply Supervisory Unit | Global Business Division | Global Business Department | |
| | | Global Supply Chain Strategy Department | |
| | | | |
| orporate Supervisory Unit | Corporate Strategy Division | Corporate Planning Department | |
| | | Finance & Accounting Department | Business Administration Office |
| | | Corporate Communications Department | |
| | | Corporate Secretariat | |
| | | | |
| | Administration Division | Human Resources Department | Human Capital Strategy Office Career Development Office |
| | | Value Chain Support Department | R&D Support Office |
| | | | Healthcare Business Support Office |
| | | General Administration Department | Treatmeare Dusiness Support Office |
| | | Legal Affairs Department | |
| | | Sustainability Management Department | |
| | | | |
| | DX Promotion Division | IT & Digital Solution Department | |
| | | Data Science Department | |
| | Corporate Quality Assurance and Ethics & Compliance Management Division | Quality Assurance Department | |
| | (General Marketing Compliance Officer) | | Promotional Compliance Office |
| | | | |